Corrected QT interval during treatment with methadone and buprenorphine-Relation to doses and serum concentrations

Drug and Alcohol Dependence

Volumn 129, Issue 1-2, 2013, Pages 88-93

  Stallvik, Marianne ^a   Nordstrand, Berit ^a   Kristensen, Øistein ^b   Bathen, Jørn ^c   Skogvoll, Eirik ^c,d   Spigset, Olav ^c,d  

^a Drug and Alcohol Treatment in Central Norway   (Norway)

^b Sørlandet Hospital   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Buprenorphine; Enantiomers; Methadone; QT interval; Serum concentration

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE; POTASSIUM;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT INTERVAL;

ADULT; ARRHYTHMIAS, CARDIAC; BUPRENORPHINE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; LINEAR MODELS; LONG QT SYNDROME; LONGITUDINAL STUDIES; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; POTASSIUM; RISK; SEX CHARACTERISTICS; TORSADES DE POINTES; YOUNG ADULT;

EID: 84875268249     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.09.016     Document Type: Article

References (35)

1. Anchersen K., Clausen T., Gossop M., Hansteen V., Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009, 104:993-999.
2. Ansermot N., Albayrak Ö, Schläpfer J., Crettol S., Croquette-Krokar M., Bourquin M., Déglon J.J., Faouzi M., Scherbaum N., Eap C.B. Substitution of (R,S)-methadone by (R)-methadone. Impact on QT interval. Arch. Intern. Med. 2010, 170:529-536.
3. Arizona Center for Education and Research on Therapeutics. QT Drug Lists. (accessed 31.07.12). http://www.torsades.org/.
4. Baker J.R., Best A.M., Pade P.A., McCance-Katz E.F. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patents. Ann. Pharmacother 2006, 40:392.
5. Benchimol A., Barthall H., Desser K. Accelerated ventricular rhythm and cocaine abuse. Ann. Intern. Med. 1978, 88:519-520.
6. Brünen S., Vincent P.D., Baumann P., Hiemke C., Havemann-Reinecke U. Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness scale. Ther. Drug Monit. 2011, 33:561-572.
7. Chiang C.N., Hawks R.L. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003, 70(Suppl. 2):S39-S47.
8. Department of Health (England) and the Devolved Administrations Drug Misuse and Dependence. UK Guidelines in Clinical Management 2007, Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive, http://www.nta.nhs.uk/uploads/clinical_guidelines_2007.pdf (accessed 31.07.12).
9. Eap C.B., Crettol S., Rougier J.-S., Schläpfer J., Grilo L.S., Déglon J.-J., Besson J., Ceoquette-Krokar M., Carrupt P.A., Abriel H. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin. Pharmacol. Ther. 2007, 81:719-728.
10. Ehret G.B., Voide C., Gex-Fabry M., Chabert J., Shah D., Broers B., Piguet V., Musset T., Gaspoz J.M., Perrier A., Dayer P., Desmeules J.A. Drug-induced long QT syndrome in injection drug users receiving methadone. High frequency in hospitalized patients and risk factors. Arch. Intern. Med. 2006, 166:1280-1287.
11. Fanoe S., Hvidt C., Ege P., Jensen G.B. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007, 93:1051-1055.
12. Fareed A., Vayalapalli S., Byrd-Sellers J., Casarella J., Drexler K., Amar R., Smith-Cox J., Luchtman T.S. Onsite QTc interval screening for patients in methadone maintenance treatment. J. Addict. Dis. 2010, 29:15-22.
13. Florian J., Garnett C.E., Nallani S.C., Rappaport B.A., Throckmorton D.C. A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients. Clin. Pharmacol. Ther. 2012, 91:666-672.
14. Fonseca F., Marit-Almor J., Pastor A., Cladellas M., Farré M., de la Torre R., Torrens M. Prevalence of long QT interval in methadone maintenance patients. Drug Alcohol Depend. 2009, 99:327-332.
15. Garrido M.J., Trocóniz I.F. Methadone: a review of its pharmacokinetic/pharmacodynamic properties. J. Pharmacol. Toxicol. 1999, 42:61-66.
16. Glassmann A.H., Bigger J.T. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry 2001, 158:1774-1782.
17. Gruner V.A., McCance-Katz E.F. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr. HIV/AIDS Rep. 2010, 7:152-160.
18. Haning W., Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction 2007, 102:70-75.
19. Huang P., Kehner G.B., Cowan A., Liu-Chen L.-Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 2001, 297:688-695.
20. + currents. J. Pharmacol. Exp. Ther. 2002, 303:688-694.
21. Krantz M.J., Lewkowiez L., Hays H., Woodroffe M.A., Robertson A.D., Mehler P.S. Torsade de pointes associated with very-high-dose methadone. Ann. Intern. Med. 2002, 137:501-504.
22. Krantz M.J., Kutinsky I.B., Robertson A.D., Mehler P.S. Dose-related effects of methadone on QT prolongation in a series of patients with torsades de pointes. Pharmacotherapy 2003, 23:802-805.
23. Krantz M.J., Garcia J.A., Mehler P.S. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsades de pointes. Pharmacotherapy 2005, 25:611-614.
24. Krantz M.J., Martin J., Stimmel B., Mehta D., Haigney M.C.P. QTc interval screening in methadone treatment. Ann. Intern. Med. 2009, 150:387-395.
25. Lin C., Somberg T., Molnar J., Somberg J. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 2009, 113:59-65.
26. Martell B.A., Arntsen J.H., Ray B., Guorevitch M.N. The impact of methadone induction on cardiac conduction in opiate users. Ann. Intern. Med. 2003, 139:154-155.
27. Martell B.A., Arnsten J.H., Krantz M.J., Guorevitch M.N. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am. J. Cardiol. 2005, 95:915-918.
28. McCance-Katz E.F., Sullivan L.E., Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am. J. Addict. 2010, 19:4-16.
29. Ohtani M., Kotaki H., Sawada Y., Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J. Pharmacol. Exp. Ther. 1995, 272:505-510.
30. Ohtani M., Kotaki H., Nishitateno K., Sawada Y., Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J. Pharmacol. Exp. Ther. 1997, 281:428-433.
31. Peles E., Bodner G., Kreek M.J., Rados V., Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients-a cross-sectional study. Addiction 2006, 102:289-300.
32. Skjervold B., Bathen J., Spigset O. Methadone and the QT interval: relations to the serum concentrations of methadone and its enantiomers (R)-methadone and (S)-methadone. J. Clin. Psychopharmacol. 2006, 26:687-689.
33. Stinger J., Welsch C., Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am. J. Health. Syst. Pharm. 2009, 66:825-833.
34. Wedam E.F., Bigelow G.E., Johnson R.E., Nuzzo P.A., Haigney M.C.P. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch. Intern. Med. 2007, 167:2469-2475.
35. World Health Organization International Classification of Diseases (ICD-10) 2012, http://www.who.int/classifications/icd/en (accessed 20.09.12).